Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination With Nivolumab in Subjects With Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT03906526 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03906526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03906526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination With Nivolumab in Subjects With Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Terminated
Start date
July 3, 2019
Completion date
January 24, 2022
Enrollment
15 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell